Colonics
 
About Me

Colonics resources

Recent Posts
Menu
Calendar
«  November 2014  »
MonTueWedThuFriSatSun
 12
3456789
10111213141516
17181920212223
24252627282930

Friends
    Links


    Entry 1 of 3188
    Last Page | Next Page
    3/17/2010 - AstraZeneca Canada's IRESSA receives approval for treatment of NSCLC
    Posted in Medical News

    AstraZeneca Canada announces the lately approved implication for IRESSA(R), a once-daily oral targeted therapy for the first-line care of work with locally elderly (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) who have activating mutations of the epidermal growth factor receptor-tyrosine kinase (EGFR-TK). In since with this approval, AstraZeneca is also hard sell the availability of a diagnostic test which can now mark a patient's EGFR mutation status, representing a new era in objectify lung cancer care in Canada.

    More: - The rest...

    Share |

    :: Send to a Friend!

    Share and enjoy
    • Digg
    • del.icio.us
    • DZone
    • Netvouz
    • NewsVine
    • Reddit
    • Slashdot
    • StumbleUpon
    • Technorati
    • YahooMyWeb